Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Completed · Phase 4 · Has a placebo group

Conditions studied: Constipation Drug Induced

In brief

The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.

Key facts

Study ID

NCT03523520

Run by

University of Missouri-Columbia

People needed

15

Starts

2020-12-23

Expected to finish

2023-03-31

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Complaint of opioid-induced constipation refractory to other therapy (enemas, laxatives, stool softeners)
• Age≥18y/o
• Not pregnant or lactating (negative urinary pregnancy test)
• No contraindication to Methylnaltrexone or Naloxegol

You may not qualify if…

• Age<18y/o
• Pregnancy or lactation
• Contraindication to Methylnaltrexone or Naloxegol
• Assigned NPO
• Small bowel obstruction

Where it is running

• Kara B. Goddard — Columbia, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.